Ascendis Pharma A/S Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Ascendis Pharma A/S on April 21, 2026. The filing announces the redemption of the Company's outstanding 2.25% Convertible Senior Notes due 2028. The redemption is triggered because the last reported sale price per ordinary share exceeded 130% of the conversion price for at least 20 trading days within the 30-day period ending April 21, 2026.
Key Financial Metrics and Transaction Details
- Debt Instrument: 2.25% Convertible Senior Notes due 2028 (CUSIP: 04351PAD3).
- Principal Amount: $575.0 million aggregate principal amount called for redemption.
- Redemption Date: May 6, 2026.
- Redemption Price: 100% of principal plus accrued interest. Approximately $1,002.19 per $1,000 principal amount.
- Standard Conversion Rate: 6.0118 ordinary shares per $1,000 principal (Conversion Price: ~$166.34).
- Make-Whole Conversion Rate: 6.3232 ordinary shares per $1,000 principal (Conversion Price: ~$158.15) applicable during the period from April 21, 2026, to May 4, 2026.
- Potential Dilution: Up to 3,456,785 shares if converted at standard rate; up to 3,635,840 shares if converted during the Make-Whole period.
The filing text does not provide current revenue, profit, cash flow, or liquidity metrics for the reporting period.
Material Changes
The primary material change is the initiation of the redemption process for the entire $575.0 million note issuance. This action is a direct result of the Company's share price performance exceeding the threshold defined in the indenture. Interest on the notes will cease to accrue on and after the Redemption Date, provided the Company does not default on payment.
Outlook, Risks, and Management Commentary
Management notes that the redemption notice constitutes a "Make-Whole Fundamental Change," increasing the conversion rate for holders who elect to convert before the deadline. Key risks identified include:
- Dilution Risk: Holders may elect to convert rather than redeem, resulting in the issuance of ordinary shares and dilution to existing shareholders.
- Liquidity Risk: The Company must have sufficient cash and liquidity to fund the Redemption Price and any cash payable in lieu of fractional shares.
- Operational Risk: Potential failure by the trustee, paying agent, or DTC to process the redemption or conversion timely.
The filing includes standard forward-looking statements disclaiming guarantees regarding the timing of payments, conversion elections, and share issuance.
Investor Verification Checklist
- Verify the Company's current cash and liquidity position to ensure it can fund the ~$575 million redemption payment on May 6, 2026.
- Monitor the conversion election rate to assess potential share dilution (up to 3.6 million shares).
- Confirm the final conversion rate and share count if the Make-Whole period adjustments are utilized.
- Review the Company's Annual Report on Form 20-F (filed February 11, 2026) for broader business risks and financial context not included in this 6-K.